CD38 was a marker gene of multiple myeloma and associated with cancer progression. Together, these results suggested that Tumor_1 cell was highly aggressive but might be more sensitive to the administrated chemotherapies while Tumor_2 cells could harbor unique features to tolerant the therapeutic pressures. Identifying the unique expression profile of Tumor_2 could shed light for future disease diagnosis and treatment selections. This evidence concerns the gene CD38 and plasma cell myeloma.